DUSP4 and cancer: The purpose of this secondary analysis was to evaluate whether the TYP—an intervention previously shown to reduce pro-tumorigenic cytokines in cancer survivors17—also significantly alters plasma levels of a panel of cognitive, metabolic and inflammatory biomarkers within the same cohort.